Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:
Back to home » Top Stories » IAC 2008
IAC 2008 XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008

Stigma, Fear of Side Effects, Keep Many off Treatment

August 6, 2008

By Tim Horn

People living with HIV around the globe still live in fear of the societal stigma that surrounds the disease, and some are so concerned about side effects that they have chosen to stop their antiretroviral (ARV) drug regimens, according to a new survey released by the International Association of Physicians in AIDS Care (IAPAC) at the XVII International AIDS Conference in Mexico City.

IAPAC worked in collaboration with a marketing research firm to conduct the AIDS Treatment for Life International Survey (ATLIS) of 2,968 HIV-positive adults—919 of whom were women—in 18 countries. To mirror the actual population with HIV, both treatment-experienced and treatment-naïve patients were recruited.

The study was funded by Merck and was conducted between March and May 2008.

One survey finding is that stigma remains an issue for HIV-positive patients, particularly with regard to disclosing their HIV status.  Fifty-four percent of those surveyed are “very” or “somewhat” concerned about others knowing their HIV status, with 83 percent claiming this is predominantly due to concern of social discrimination and stigma. Respondents also expressed concern about specific repercussions, including loss of family and friends (41 percent), the impact on their ability to establish future relationships (37 percent), the risk of losing their jobs (36 percent) and the impact on their reputation (36 percent).

African respondents had fewer concerns about revealing their condition as opposed to respondents in other regions. Asian/Pacific respondents were more concerned about the risk of losing family and friends, as well as the potential impact on their current relationships. Respondents in North America were most concerned that their HIV-positive status could damage their reputation.

A second major finding of the survey is that many are concerned about ARV side effects and, as a result, avoid or stop HIV treatment. Overall, 26 percent of the respondents reported that they had elected not to seek treatment because they believe that ARV therapy causes too many side effects, with responses from Europe (42 percent) and South Africa (29 percent) being most prevalent.  What’s more, 34 percent of treatment-experienced survey respondents discontinued ARV therapy primarily because they believe it caused too many side effects.

Side effects that survey respondents are most worried about include lipodystrophy, lipoatrophy and other body-shape changes (58 percent of survey respondents); gut-related problems such as nausea and diarrhea (54 percent); fatigue or anemia (54 percent); and liver disease (54 percent).

Respondents in Latin America and North America voiced significantly more concern about many potential side effects than respondents from other regions, while African respondents voiced significantly less concern.  

Female respondents in most regions, especially those in Europe, worried more than male respondents in their respective regions about bone loss and face or body shape changes.

“ATLIS results indicate there is still a strong need to educate HIV-positive patients and the world around them. The findings demand an increase in global HIV and AIDS literacy,” said José Zuniga, PhD, president and CEO of IAPAC. “It is critical that we empower HIV-positive patients to take an active part in the management of their disease by educating them on the importance of adhering to their treatment and teaching them about the innovations in treatment that could improve their overall quality of life.”

 

Scroll down to comment on this story.

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 3 (of 3 total)    

Annette, New Jersey, 2008-11-11 19:10:30
I was asked to speak about "stigma and HIV" --- and just started to write some notes for my speech (which is - uh, tomorrow). After all I've been through, the stigma has to be the worst. Overcoming the ignorance surrounding HIV has become my life's mission. I do it one person at a time. Hopefully, our new President will finally address HIV/AIDS by FINALLY implementing a National AIDS strategy. Stigma can only be abated through education and good policy.

baffled, The Hague, 2008-09-06 17:14:28
I think STOPPING treatment with no alternatives is ill advised. Why did you start in the first place? Doing good? I am scared for you. Its not about intellectual knowledge but a living virus fighting your immunity, PLEASE.

irenemuga, nairobi, 2008-08-22 04:13:01
i stopped drugs due to many side effects. am now 6 mths free of drug, and am doing good. a know quite abit abt arv's, i have done courses on the same, adherence included, but am not re-starting!

comments 1 - 3 (of 3 total)    

Our general International AIDS Conference coverage is made possible with a charitable grant from Bristol-Myers Squibb.

More from IAC 2008

Starting and Switching Treatment

August 12, 2008
Isentress, Intelence and Prezista Combo Shines for Treatment Veterans
Studies Disagree on Abacavir for Patients With High Viral Loads
August 6, 2008
Isentress Continues to Show Well Versus Sustiva as First-Line Treatment
Stigma, Fear of Side Effects, Keep Many off Treatment
Sustiva Bests Kaletra for Treatment of Advanced HIV Disease
August 5, 2008
Some Gender and Racial Differences with Three Protease Inhibitors
August 4, 2008
Similar Survival Among IDUs on ARV Treatment

HIV/AIDS Complications

August 15, 2008
Milk Thistle Shows Potential for Hep C
August 14, 2008
Defining the Risk Factors for Kidney Damage in Patients Using Tenofovir
August 13, 2008
Encouraging Data From Second Tesamorelin Study for Lipo
August 11, 2008
Abacavir and Cardiovascular Risk: Is There or Isn’t There?
August 7, 2008
Abacavir and Heart Attack Risk: Round 2
August 6, 2008
Hep C: The Other Epidemic

Experimental HIV Drugs

August 15, 2008
Norvir Tablets Similar to Capsules, Expected in 2009
August 12, 2008
Future Options for the Treatment Experienced
New Options for Those New to Treatment
August 11, 2008
IDX899 Safe, Reduces Viral Load in Preliminary Study
August 8, 2008
New NNRTI RDEA806 Shows Promise in Seven-Day Study
August 6, 2008
NNRTI Rilpivirine (TMC-278) Comparable to Sustiva in 96-Week Study

HIV Transmission and Prevention

August 18, 2008
Vaccines: Lessons Learned
August 15, 2008
PrEP: Preparing For Success?
August 14, 2008
New HIV Numbers: New Prevention Strategy? Part 1
New HIV Numbers: New Prevention Strategy? Part 2
August 7, 2008
Microbicides: Assessing Progress
Having Children a Priority for Many Positive Women
August 5, 2008
Report: Now Is Time to Prepare for PrEP
August 3, 2008
Annual HIV Infections in U.S. Substantially Higher Than Believed

Global HIV/AIDS

August 19, 2008
AIDS Activism For The Next Decade
August 15, 2008
Human Rights Struggles Define AIDS Fight
August 8, 2008
Achieving Universal Treatment Access: The Experience in Rural Malawi
August 6, 2008
Stigma, Fear of Side Effects, Keep Many off Treatment
August 4, 2008
Shortage of Health Care Workers Threatens African HIV Care
IAC Panelists: Scale Up, Leadership and Youth Crucial to HIV Response

Regan's Blog

August 6, 2008
La Voz Global
August 4, 2008
Bienvenidos a AIDS 2008!


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy